WCLC 2017: Plasma ctDNA Analysis In EGFRm-Positive Patients With Advanced NSCLC
Results from the FLAURA trial support the use of plasma circulating tumor DNA (ctDNA) analysis to determine patients’ eligibility for first-line treatment with osimertinib. The phase III randomized trial, which evaluated patients with epidermal growth factor receptor–mutated (EGFRm) non–small cell lung cancer (NSCLC), found that treatment with osimertinib reduced the risk of disease progression, and the data also demonstrated concordance between tissue and plasma testing for the mutation. These findings were presented by Jahnelle Elaine Gray, MD, of Moffitt Cancer Center, Tampa, Florida, at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 5.02) in Yokohama, Japan.
This study evaluated a subset of 556 patients from the FLAURA trial. Approximately half received osimertinib, and the other half received the standard of care, EGFR–tyrosine kinase inhibitor. The investigators focused on a subset of plasma EGFRm–positive patients. At baseline, patients provided tumor tissue samples for central analysis of EGFRm status as well as blood samples for retrospective analysis by plasma ctDNA.
Osimertinib reduced the risk of disease progression or death by 56% compared with the standard of care in this subset of patients, with a hazard ratio of 0.44. These findings were consistent with the overall progression-free survival reported with osimertinib versus standard of care in the full FLAURA analysis set.